Qnexa (Vivus Inc) Phase III results published in Obesity

Phase III data for Qnexa ((phentermine plus topiramate) from Vivus Inc., of the 56-week EQUIP study have been published in Obesity, the peer-reviewed journal of The Obesity Society. The trial evaluated the efficacy and safety of Qnexa in 1,267 severely obese (BMI >/= 35 kg/m2) patients in the USA. In addition to an average weight loss of 14.4% of initial body weight in those who completed the study at the top dose of Qnexa, severely obese patients had improvements in blood pressure, glucose, triglycerides and cholesterol. see Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) David B. Allison, Kishore M. Gadde, William Timothy Garvey, Craig A. Peterson, Michael L. Schwiers, + et al Obesity doi:10.1038/oby.2011.330 Among patients who completed the top-dose course of treatment, 83.5% lost >/= 5%; 67.7% lost >/= 10%; and 48.1% lost >/= 15% of their baseline weight.